COMPOSICIONES VACUNALES A BASE DE STICHOLISINA ENCAPSULADA EN LIPOSOMAS

SE REFIERE A UNA COMPOSICION DE VACUNA QUE CONTIENE UN VEHICULO PARA VACUNA QUE INDUCE UNA RESPUESTA INMUNE CELULAR Y COMPRENDE LA ENCAPSULACION EN VESICULAS LIPIDICAS DE PROTEINAS OBTENIDAS DE LA ANEMONA STICHODACTYLA HELIANTHUS TAL COMO StIW111C, StIW111Cirrev O StII INACTIVADA POR TRATAMIENTO TERMICO JUNTO CON UN ANTIGENO QUE ES UNA PROTEINA O POLIPEPTIDO ASOCIADO AL CANCER, SIDA O TUBERCULOSIS; EN DONDE LOS LIPOSOMAS SON OBTENIDOS POR EL PROCEDIMIENTO DE DESHIDRATACION-REHIDRATACION CUYA COMPOSICION LIPIDICA ES DIPALMITOILFOSFATIDILCOLINA:COLESTEROL EN UNA RELACION MOLAR 1:1 The current invention relates to the field of Biotechnology applied to human health. Here it is described a vaccine vehicle wherein toxins from eukaryotic organisms are encapsulated into multilamellar vesicles obtained by the dehydration-rehydration procedure whose lipidic composition is dipalmitoylphosphatidylcholine: cholesterol in a 1:1 molar ratio for subcutaneous or intramuscular administration. These compositions do not require the use of other adjuvants. The disclosed compositions allow modulation of CTL-specific immune response against one or several antigens co-encapsulated into toxin-containing liposomes. The vaccinal vehicle of the present invention shows advantages over others disclosed by the previous art due to the robustness and functionality of the induced immune response as well as its immunomodulating properties.